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Abstract
Background: Case review and discussion at multidisciplinary team meetings (MDTMs) have evolved into standard
practice in cancer care with the aim to provide evidence-based treatment recommendations. As a basis for work to
optimize the MDTMs, we investigated participants’ views on the meeting function, including perceived benefits and
barriers.
Methods: In a cross-sectional study design, 244 health professionals from south Sweden rated MDTM meeting structure
and function, benefits from these meetings and barriers to reach a treatment recommendation.
Results: The top-ranked advantages from MDTMs were support for patient management and competence development.
Low ratings applied to monitoring patients for clinical trial inclusion and structured work to improve the MDTM. Nurses
and cancer care coordinators did less often than physicians report involvement in the case discussions. Major benefits
from MDTM were reported to be more accurate treatment recommendations, multidisciplinary evaluation and adherence
to clinical guidelines. Major barriers to a joint treatment recommendation were reported to be need for supplementary
investigations and insufficient pathology reports.
Conclusions: Health professionals’ report multiple benefits from MDTMs, but also define areas for improvement, e.g.
access to complete information and clarified roles for the different health professions. The emerging picture suggests
that structures for regular MDTM evaluations and increased focus on patient-related perspectives should be developed
and implemented.
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Background
Multidisciplinary team meetings (MDTMs) have widely
been implemented in cancer care based on the principle
that interdisciplinary case discussions lead to improved
treatment recommendations based on updated and
evidence-based knowledge or expert opinion. The MDTM
structure is broadly considered to improve communication,
coordination and decision making [1]. The MDTM is part
of the weekly clinical duties for most physicians, nurses and
coordinators in cancer care, links clinical information from
various sources and represents a pivotal point of the patient
care pathway. Benefits from MDTMs relate to improved
care processes, adherence to clinical and up-to-date treat-
ment recommendations, which have been documented in
several cancer types [2–8]. Other potential benefits include
shorter lead times, increased attention to patient-related
perspectives, competence development, training opportun-
ities for younger colleagues and the possibility to identify
patients eligible for clinical trials [8]. Studies on the relation
between MDTM, quality of care and survival have reached
different conclusions, potentially explained by differences in
study design, MDTM format, case selection and different
diagnoses studied [2, 4, 6, 7, 9]. Core MDTM expertise var-
ies between diagnoses, but typically includes surgeons,
medical oncologists, radiation therapists, radiologists and
pathologists. More recently, experts in nuclear medicine
and molecular pathology, contact nurses, research nurses
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and cancer care coordinators have been added to the multi-
disciplinary team. Greater multidisciplinarity is, however,
not necessarily associated with more effective decision-
making and treatment implementation [9].
A number of issues will influence the benefit from a
MDTM, e.g. participation from qualified and effective
experts, case selection, access to relevant information,
discussion format and structure, leadership, health pro-
fessionals’ interactions, technical equipment and admin-
istrative processes [9, 10]. Most MDTMs are held on a
weekly basis, though a recent focus on shorter lead
times and efficient diagnostic processes in Swedish
cancer care has led to biweekly meetings in select
diagnoses and hospitals. A growing number of MDTMs
are video-based with regional or national participation.
Though there is general agreement of the value of
MDTM, the structure is also questioned since it is re-
source-demanding due to an increasing cancer incidence,
participation from a growing number of experts, increased
meeting frequency to grant timely treatment, evaluation
based on refined diagnostic methods and more complex
treatment algorithms. Information on the structure and
function of individual MDTMs is scarce and a wide variety
of meeting standards has been documented [4, 9, 11]. To
provide a basis for structured and targeted improvements
in cancer care, we investigated health professionals’ views
on MDTMs, including perceived benefits from MDTM-
based recommendations and barriers to reach joint rec-
ommendations, with correlation to discipline, profession,
hospital type and diagnostic area.
Methods
We performed a cross-sectional study on health profes-
sionals’ views of MDTMs. Data was based on an electronic
survey that was distributed to all identified participants in
the 50 MDTMs in the south Sweden health care region.
This region has a population of 1.8 million and provides
specialized cancer care services provided by one Univer-
sity hospital and six county hospitals. These 50 MDTMs
were initially identified in a study on the determinants of
MDTM costs, which has recently been presented and doc-
uments a mean MDTM duration of 0.88 h, mean 12.6
cases discussed and a mean cost per case discussion of
212 (range 91–595) EUR [12]. The MDTM meetings were
held on a weekly basis and included 19 meetings at local
hospitals and 31 meetings at the University hospital. Of
the 50 MDTMs, 19 were video-based regional and two
were video-based national MDTMs with participation
from health professionals from other hospitals. A list of
MDTM participants was provided by the cancer care co-
ordinators at each hospital. All participants in these 50
MDTMs were eligible for the study. A small number (<
10) individuals participated in more than one weekly
MDTM and were assigned to the predominant diagnosis
and meeting base on impact, i.e. from leading the meeting
or from the number of case discussions. In total, 362 par-
ticipants were identified to whom study invitations ac-
companied by a link to the electronic survey were
distributed by e-mail.
We constructed an electronic survey (Surveymonkey.-
com) with three parts; a first part with five demographic
questions and information on weekly MDTM participa-
tion times, a second part where the informants were
asked to rate 20 statements on MDTM structure and
function and a third part where the informants were
asked to prioritize up to three possible benefits from
MDTM and up to three potential barriers for shared
MDTM recommendations (Additional file 1) . The ques-
tionnaire was constructed by the research group, was in
Swedish and the contents related to benefits, barriers
and choice of statements were largely collected from
previous publications in the field. Data on validity and
reliability are not available, but prior to data collection
the questionnaire underwent pilot testing in five MDTM
participants from various disciplines and professions.
The demographic questions included data on age, sex,
profession (physician vs nurse/coordinator), hospital
type (county vs university hospital) and discipline (sur-
gery, medicine, radiology, pathology). Surgery included
general surgery, urology, thoracic surgery, neurosurgery,
vascular surgery, orthopedic surgery and gynecology.
Medicine included medical oncology and radiation on-
cology, pediatric oncology, hematology, pulmonology,
endocrinology and neurology. Radiology included radi-
ology, nuclear medicine and clinical physiology. Cancer
care coordinators represent a new role in Swedish health
care with responsibilities for booking and coordinating
diagnostic and therapeutic procedures. Since the number
of coordinators was low, this group was analyzed
together with the nurses.
Health professionals’ views on MDTMs were evalu-
ated based on 20 statements that the respondents
were asked to rate on a seven-point Likert scale from
1 (strongly disagree) to 7 (strongly agree) with a pos-
sibility to answer “do not know/not applicable”. The
statements referred to the participants’ individual
competence and their roles at the MDTM (n = 3),
functional aspects of the conference, e.g. guidelines
for referral and documentation, technology, availabil-
ity of relevant information (n = 11) and overall impact
from MDTM recommendations e.g. perceived benefits
for patient management, education and training, clin-
ical study inclusion and use of resources (n = 6). To
collect information on perceived benefits and barriers,
the respondents were asked to select the three out of 13
most important benefits of MDTMs and the three out of
15 most important barriers to reaching a joint treatment
recommendation. Respondents who provided one to three
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responses were considered in the further analyses. The al-
ternatives defined in the survey were selected from previ-
ous publications [9–11, 13–15]. All data are available from
the corresponding author upon request.
The response profiles were analyzed in relation to pro-
fessions, disciplines, hospital types and cancer-specific
MDTMs. All statistical analyses were performed in R,
version 3.2.2 [16]. Benefits of MDTMs and barriers to
reaching a joint recommendation were analyzed using
chi squared tests with significance set at p = 0.05. Data
on opinions of MDTMs based on Likert scale data are
presented in a diverging stacked bar chart and were ana-
lyzed using chi squared tests. Bonferroni correction was
applied to correct for multiple testing.
Results
Complete responses that allowed for further analyses
were obtained from 244 of 362 (67%) MDTM partici-
pants. Further analysis of non-responders was not pos-
sible due to lack of data on this subset. Of the
respondents, 56% were women. The age distribution was
2% in the age group 20–29 years, 13% 30–39 years, 33%
40–49 years, 33% 50–59 years and 19% of the respon-
dents were ≥ 60 years of age. Of the respondents, 70%
were physicians and 28% were nurses and coordinators.
Discipline was surgery in 47%, medicine in 29%, radi-
ology in 14% and pathology in 7%. Hospital type was
52% university hospital and 48% county hospitals. The
respondents represented teams from various cancer
diagnoses: 27% gastrointestinal and hepatobiliary cancer,
21% breast cancer and malignant melanoma, 19% uro-
logical and gynecological cancer, 19% lung cancer and
12% other tumors, i.e. head and neck tumors, CNS
tumors, sarcomas and endocrine tumors.
The respondents’ views on MDTMs are summarized
in Fig. 1. Overall, affirmative scores were given to the
majority of the statements. Agreement (scores 5–7) was
particularly strong for provides support for further
patient management (94%), develops competence of jun-
ior colleagues (93%) and develops individual competence
(92%). The two issues that received the lowest fraction
of affirmative responses were pathology reports are final-
ized in time (48%) and we (i.e. the MDT) work to develop
the MDTM (30%). The responses were consistent with-
out major differences in relation to profession, discipline,
hospital type or cancer-specific MDT. No significant dif-
ferences applied for scores 1–3, whereas minor differ-
ences were identified for the affirmatory responses.
Nurses and coordinators did more often than physicians
agree to MDTM being resource efficient (88% vs 69%, p
= 0.008) and all cancer patients should be discussed at
MDTMs (74% vs 49%, p = 0.0015), but did less often
report being involved in the discussions (57% vs 90%, p =
0.0005). The views also differed between cancer-specific
MDTMs related to whether all cancer patients should be
discussed in MDTMs, which was supported by a major-
ity of members in teams working with breast cancer, GI
cancer and other tumors (53–78%), but to a lesser extent
in teams working with lung cancer and urological-
gynecological cancer (31–38%) (p = 0.0005).
Analyses on the most important benefits of MDTM
were based on answers submitted by 203 respondents.
The two predominant benefits were compiled clinical in-
formation and review results in more accurate treatment
Fig. 1 Respondents’ views on MDTMs. Diverging stacked bar chart demonstrating the frequency of different levels of agreement on 20
statements. Scores from 1 (strongly disagree) to 7 (strongly agree)
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recommendations (81%) and multidisciplinary evalu-
ation (67%), followed by promotes adherence to clinical
guidelines (34%), increases team competence (26%) and
increases patient safety (22%) (Fig. 2). The two reasons
that were the least selected were attention to patient
preferences (1%) and identification of patients suitable
for clinical trials (3%). Perceived benefits of MDTM dif-
fered between various health care profession, discipline
and hospital type, but was not influenced by the cancer
field served (Table 1). Nurses and coordinators more
often than physicians (28% vs 9%, p < 0.001, significant
after Bonferroni correction) considered shortened time
from diagnosis to treatment as a major benefit of MDTM.
Pathologists did more often than physicians of other dis-
ciplines refer to strengthens teamwork (43% vs 7–11%, p
= 0.005). Health professionals working in university hos-
pitals did more often than those employed at county
hospitals report increases team competence as a major
benefit of MDTM (34% vs 19%, p = 0.015), whereas pro-
fessionals in county hospitals more often selected multi-
disciplinary evaluation (75% vs 59%, p = 0.026).
Analyses of the most common barriers to reaching
a joint recommendation were based on answers sub-
mitted by 216 respondents. The predominant barriers
were need for supplementary investigations (87%) and in-
sufficient pathology (65%), followed by no professional
present has seen the patient (25%), complex cases (24%)
and insufficient radiology (20%) (Fig. 3). Patient prefer-
ences, insufficient leadership, insufficient teamwork, dis-
agreement, insufficient preparations, interruption or
distraction and lack of time were rare causes, reported by
0–2% of the respondents. Reported barriers differed be-
tween professions, hospital types, disciplines and cancer-
specific MDTMs (Table 2). Physicians did more often
than nurses and coordinators (29% vs 13%, p = 0.024) refer
to no professional present has seen the patient. Complex
cases were reported by 37% of physicians in medicine
compared to 29% of pathologists, 20% of surgeons and
14% of radiologists (p = 0.049). Complex cases were also
more often referred to by professionals in the university
hospital than in county hospitals (33% vs 17%, p = 0.005).
Health care personnel at the university hospital did more
often than personnel in county hospitals refer to absence
of key professionals (17% vs 7%, p = 0.04). In contrast,
health professionals in county hospitals more frequently
chose insufficient pathology (73% vs 56%, p = 0.015) and
no professional present has seen the patient (31% vs 18%,
p = 0.024). Minor differences were observed between the
cancer-specific MDTMs related to no professional
present has seen the patient, which was rarely identi-
fied in the breast cancer teams (p = 0.002, significant
after Bonferroni correction), and disagreement on the
recommendations, which was more commonly re-
ported from members in urological and gynecological
MDTM teams (p = 0.015) (Table 2).
Discussion
Health professionals who participate in cancer-related
MDTMs report an overall positive attitude, but also
identify key issues for improvement, which fits with
reports from other health care systems [2, 4]. MDTMs
are typically chaired by physicians and more recent in-
clusion of nurses and coordinators in the meetings has
been reported to improve team performance [17]. We
identified differences between physicians and nurses/co-
ordinators related to the estimated impact from MDTM
on time to treatment, resource-efficiency and involve-
ment in the case discussions. Nurses and coordinators
did more often (28% vs 14%) refer to MDTMs contribut-
ing to shorter time to treatment, which may reflect that
nurses and coordinators who participate in MDTM may
immediately plan and book further procedures and treat-
ments. Whereas the views on development of individual
competence did not differ between physicians and
nurses/coordinators, the latter group reported being less
involved in the case discussions. An observing rather
Fig. 2 Benefits of MDTMs. Respondents were asked to choose the reasons they considered most important, maximally three. Percentages refer to
the total number of respondents (n = 203)
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than an interacting role of nurses in MDT meetings has
been reported also by other investigators with reports
that the medical perspectives dominate over care per-
spectives during MDTMs [18, 19]. An important aspect
of improvement of MDTMs relate to an appropriate skill
mix of a multidisciplinary team and development and
implementation of MDTM structures and procedures
[20]. These observations suggest that the roles of nurses
and coordinators should be highlighted to improve
MDTM function. Responsibilities that could be targeted
to nurses include consideration of comorbidity, psycho-
social aspects, rehabilitation and supportive care needs,
patient preferences and relevant clinical trials [19]. Can-
cer care coordinators could take responsibility for all
relevant documentation being available prior to the case
discussions [18, 20].
Though many MDTM groups struggle with how to
best include patient-related perspective in the decision
process, a limited focus on these aspects have been doc-
umented in several studies [21]. Restivo et al. found that
psychological, socio-demographic and relational aspects
were discussed in 30% of the cases and patient’ prefer-
ences were discussed in 10% of the cases at MDTMs in
French health care [22]. Divergent treatment priorities
between physicians and patients have been demonstrated
in multiple studies and cancer types. If the MDTM aims
to contribute to individualized treatment decisions and
implementation of the MDTM’s recommendations, pa-
tient values and preferences need to be considered. Our
data demonstrate that in Swedish health care 78% of
health professionals agree that patient preferences
should be commented on during the MDTMs, but only
1% of the respondents identify patient perspectives as a
major benefit from MDTMs (Figs. 1 and 2). The need to
consider comorbidities was supported by 87% of the re-
spondent and 17% considered comorbidity to be a major
barrier for a joint MDTM recommendation (Figs. 1 and
3). Leadership and interactions between the MDTM par-
ticipants are central in this process. MDTM leaders
often express a clear view on the optimal treatment rec-
ommendation. Team members may counteract this by
providing additional patient-related information,
which may influence the further discussion, though per-
haps based on fragmented and selected information
[22]. Additionally, when the information is conveyed to
the patient, it needs to be balanced, which requires that
controversies and differences in opinion have been clarified.
Current observations suggest that though the premises of
multidisciplinary care involve addressing patients’ needs,
routines for how this should be granted at the MDTM need
to be developed and will likely require substantial revision
of the current meeting structure [9, 23–26].
The MDTM may be a suitable and relevant time point
to consider patients for inclusion into clinical trials. In
our data, 74% of the respondents supported that the
MDTM could be used for this purpose, but only 3%
identified this as a key benefit of MDTMs. Training for
multidisciplinary teams in communication around clin-
ical studies has been implemented and evaluated in the
UK with promising results related to ease of communi-
cation and understanding of the impact for trial inclu-
sion [27].
The two most important benefits from MDTMs were
reported to be treatment recommendations based on
compiled clinical information and multidisciplinary
evaluation, followed by adherence to guidelines,
Fig. 3 Barriers to joint recommendations in MDTMs. Respondents were asked to choose the barriers they considered most common, maximally
three. Percentages refer to the total number of respondents (n = 216)
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increased team competence and patient safety (Fig. 2).
Reference to increased competence and strengthened
team work fits well with data from an international survey
that report that seeking advice on treatment recommen-
dation and participation in multidisciplinary discussion
were the main reasons for MDT attendance [28]. The
MDTM may also improve communication, positively influ-
ence the work environment and is an important part of
continuous medical education [28]. In our study, MDTMs
were considered more valuable for training of younger col-
leagues/residents (93%) than for education of undergradu-
ate students (65%) (Fig. 1). Health professionals at the
university hospital did more often (34% vs 19%) than their
colleagues in local hospitals refer to the MDTM contribut-
ing to an improved team competence. Pathologists did sig-
nificantly more often (43% vs 7–11%) than other disciplines
refer to teamwork as an important benefit of the MDTM,
which most likely reflects differences in working cultures
between pathologists, who independently diagnose cases,
and other disciplines, where teamwork is part of the every-
day clinical work.
Failure to reach a joint recommendation has been re-
ported to occur in 6–52% of case discussions during
MDTMs [16, 28]. Considering the increasing demand for
meeting time, efforts to reduce this figure are important.
The main barriers to reach a joint recommendation iden-
tified in our study were need for supplementary investiga-
tions and insufficient pathology, followed by no
professional present who had seen the patient and com-
plex cases (Fig. 3). Absence of key professionals was more
frequently (17% vs 7%) reported from the university hospi-
tals than the county hospitals, which may reflect a vulner-
able access to highly specialized competences. The
participants rated compiled clinical information as one of
the most important benefits from MDTM, but at the same
time identified insufficient clinical information as a main
barrier for a joint recommendation, which is supported
also by observations from other health care systems [16,
29]. Though poor leadership, insufficient teamwork, dis-
agreement and time pressure were by the respondents
identified as less important, other studies have docu-
mented that factors such as poor leadership, insufficient
teamwork, disagreement and time pressure as barriers for
efficient MDTM recommendations [17, 21]. MDTM
case reviews have been shown to change the initial
treatment plan in up to a third of the cases, with the
highest likelihood in complex cases [22, 28, 30, 31].
In our study, complex cases were more often (33% vs
17%) identified as barriers for recommendations by
MDTM members at the university hospital compared
to county hospitals. This difference likely reflect case
selection and underscores the need for highly special-
ized competences for high-quality case evaluations
and the need for the MDTM team to define core
competences and support these members in improvement
initiatives related to efficient decision-making.
Guidelines for which patients should be discussed at
MDTMs should regularly be reviewed since the benefit
of multidisciplinary evaluation and the need for core
expertise likely differs between cancer types, tumor sub-
sets, disease stages and patient subgroups. Of the respon-
dents, 61–64% were positive to targeted approaches, e.g.
listing of standard cases without detailed discussion or
mini-MDTMs with selected disciplines present. Alterna-
tive case discussion formats were in our study supported
by teams in lung cancer and urological and gynecological
cancer and support for prioritization has in previous stud-
ies been gained from e.g. urological and colorectal cancer
[13, 30]. Though data on the use of mini-MDTM are
scarce, this principle has been suggested to be time and
resource saving compared to full MDTMs [28, 31].
Only 30% of the respondents reported work to develop
the MDTMs, though use of e.g. independent observers or
evaluation instruments have been shown to change case
management and improve MDTM quality. Several instru-
ments have been developed and have performed favorably
related to validity and interrater reliability [11, 32–34].
Work to optimize MDTM recommendations need to con-
sider the MDTM function as well as the implementation
rate of the recommendations made with careful consider-
ation of shortcomings and differences in views between
the participants [9].
Strengths of the study include a population-based ap-
proach with participation from all MDTMs in our health
care region, a 67% response rate and a large sample size,
which allows for subgroup-specific analyses in relation
to professions, disciplines, hospital type and cancer-
specific MDTs. Weaknesses relate to our development of
a questionnaire the results of which cannot readily be
compared to other studies. The perceived benefits and
barriers to MDTMs were largely restricted to issues pre-
viously identified in scientific studies. Use of select state-
ments and predefined benefits and barriers risks
overseeing less common perspectives, although the
informants could provide free text comments. Further-
more, since standardized MDTM improvement pro-
grams have not been implemented in Sweden, the input
from health professionals could not be studied in
relation to whether the MDTM in question was well-
functioning or not.
Conclusions
Health professionals in Swedish cancer care are overall
positive to MDTMs, but also identify several shortcom-
ings. Nurses and coordinators report being less active in
the case discussions. MDTMs are rarely used to screen
patients for inclusion into clinical trials. The focus on
patients-related perspectives and preferences is weak.
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Only one-third report structured work to evaluate and
improve the MDTM function. Considering the increasing
needs for MDTM and the considerable resources invested,
these observations call for implementation of regular
MDT evaluations and further research on how to best im-
prove MDTM efficacy.
Practical implementation
Health professionals report strong benefits from MDTM
related to support for further patient management and
professional competence development and identify
issues for improvement that include finalized pathology
reports prior to the meeting and implementation of
structured work to improve MDTM function. Nurses
and cancer care coordinators did more often than physi-
cians perceive that the meetings were resource efficient,
but did less often than physicians report being involved
in the case discussions. Predominant MDTM benefits
were compiled clinical information and review, multidis-
ciplinary evaluation and adherence to clinical guidelines.
Major barriers to reach a joint treatment recommenda-
tion were the need for supplementary investigations and
insufficient pathology. These issues would be valuable to
consider in future MDTM improvement programs.
Additional file
Additional file 1: Questionnaire. Electronic survey distributed by e-mail
to MDTM participants (n = 362). (PDF 315 kb)
Abbreviations
MDTM: Multidisciplinary team meeting
Acknowledgements
The authors would like to acknowledge the MDTM participant for providing
data to the study and the cancer coordinators in Region Skåne, Region
Halland, Region Kronoberg and Landstinget Blekinge for help in identifying
MDTMs and participants.
Funding
This study was supported by grants from the Swedish Cancer Fund, and the
Region Skåne ALF funds.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on request.
Authors’ contributions
LR, NA, OH and MN have all made substantial contributions to conception
and study design, data acquisition, analysis and data interpretation, have
been involved in drafting and revising the manuscript, given final approval
of the version to be published and have agreed to be accountable for all
aspects of the work.
Ethics approval and consent to participate
Ethics approval was obtained from the Regional Ethical Review Board in
Lund (reference number: 2016/195). All respondents were informed about
the study purposes and gave consent to participate.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Institute of Clinical Sciences, Division of Oncology and Pathology, Lund
University, Scheelev. 2, 223 63 Lund, Sweden. 2Regional Cancer Centre South,
Region Skåne, Sweden. 3Clinical Research Centre, Copenhagen University
Hospital, Hvidovre, Denmark. 4Danish Cancer Society Research Center,
Copenhagen, Denmark.
Received: 9 March 2017 Accepted: 14 March 2018
References
1. El Saghir NS, Keating NL, Carlson RW, Khoury KE, Fallowfield L. Tumor
boards: optimizing the structure and improving efficiency of
multidisciplinary management of patients with cancer worldwide. Am Soc
Clin Oncol Educ Book. 2014;34:e461–6.
2. Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, et al. The
impact of multidisciplinary team meetings on patient assessment,
management and outcomes in oncology settings: a systematic review of
the literature. Cancer Treat Rev. 2016;42:56–72.
3. Brannstrom F, Bjerregaard JK, Winbladh A, Nilbert M, Revhaug A, Wagenius
G, et al. Multidisciplinary team conferences promote treatment according to
guidelines in rectal cancer. Acta Oncol. 2015;54(4):447–53.
4. Prades J, Remue E, van Hoof E, Borras JM. Is it worth reorganising cancer
services on the basis of multidisciplinary teams (MDTs)? A systematic review
of the objectives and organisation of MDTs and their impact on patient
outcomes. Health policy (Amsterdam, Netherlands). 2015;119(4):464–74.
5. Freeman RK, Ascioti AJ, Dake M, Mahidhara RS. The effects of a
multidisciplinary care conference on the quality and cost of Care for Lung
Cancer Patients. Ann Thorac Surg. 2015;100(5):1834–8. discussion 8
6. Pan CC, Kung PT, Wang YH, Chang YC, Wang ST, Tsai WC. Effects of
multidisciplinary team care on the survival of patients with different
stages of non-small cell lung cancer: a national cohort study. PLoS One.
2015;10(5):e0126547.
7. Munro A, Brown M, Niblock P, Steele R, Carey F. Do multidisciplinary team
(MDT) processes influence survival in patients with colorectal cancer? A
population-based experience. BMC Cancer. 2015;15:686.
8. Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil
BJ. Tumor boards and the quality of cancer care. J Natl Cancer Inst.
2013;105(2):113–21.
9. Raine R, Wallace I, Nic a’ Bhaird C, Xanthopoulou P, Lanceley A, Clarke A, et
al. Improving the effectiveness of multidisciplinary team meetings for
patients with chronic diseases: a prospective observational study. Health
Serv Del Res. 2014;2(37):1–72.
10. Lamb B, Green JS, Vincent C, Sevdalis N. Decision making in surgical
oncology. Surg Oncol. 2011;20(3):163–8.
11. Taylor C, Atkins L, Richardson A, Tarrant R, Ramirez AJ. Measuring the quality
of MDT working: an observational approach. BMC Cancer. 2012;12:202.
12. Alexandersson N, Rosell L, Wihl J, Ohlsson B, Steen Carlsson K, Nilbert M.
Determinants of variable resource use for multidisciplinary team meetings
in cancer care. Acta Oncol. 2017;3:1–6.
13. Lamb BW, Jalil RT, Sevdalis N, Vincent C, Green JS. Strategies to improve the
efficiency and utility of multidisciplinary team meetings in urology cancer
care: a survey study. BMC Health Serv Res. 2014;14:377.
14. The characteristics of an effective multidisciplinary team (MDT): National
Cancer Action Team; 2010. Available from http://www.ncin.org.uk/cancer_
type_and_topic_specific_work/multidisciplinary_teams/mdt_development
15. Lamb BW, Taylor C, Lamb JN, Strickland SL, Vincent C, Green JS, et al.
Facilitators and barriers to teamworking and patient centeredness in
multidisciplinary cancer teams: findings of a national study. Ann Surg Oncol.
2013;20(5):1408–16.
16. Team RC. R: a language and environment for statistical computing. Vienna:
R Foundation for Statistical Computing; 2015.
Rosell et al. BMC Health Services Research  (2018) 18:249 Page 9 of 10
17. Lamb BW, Brown KF, Nagpal K, Vincent C, Green JS, Sevdalis N. Quality of
care management decisions by multidisciplinary cancer teams: a systematic
review. Ann Surg Oncol. 2011;18(8):2116–25.
18. Jalil R, Lamb B, Russ S, Sevdalis N, Green JS. The cancer multi-disciplinary
team from the coordinators’ perspective: results from a national survey in
the UK. BMC Health Serv Res. 2012;12:457.
19. Punshon G, Endacott R, Aslett P, Brocksom J, Fleure L, Howdle F, et al. The
experiences of specialist nurses working within the uro-oncology
multidisciplinary team in the United Kingdom. Clinical Nurse Spec. 2017;
31(4):210–8.
20. Nancarrow S, Booth A, Ariss S, Smith T, Enderby P, Roots A. Ten principles of
good interdisciplinary team work. Hum Resour Health. 2013;11:19.
21. Lamb BW, Sevdalis N, Arora S, Pinto A, Vincent C, Green JS. Teamwork
and team decision-making at multidisciplinary cancer conferences:
barriers, facilitators, and opportunities for improvement. World J Surg.
2011;35(9):1970–6.
22. Restivo L, Apostolidis T, Bouhnik A-D, Garciaz S, Aurran T, Julian-Reynier C.
Patients’ non-medical characteristics contribute to collective medical
decision-making at multidisciplinary oncological team meetings. PLoS One.
2016;11(5):e0154969.
23. Hamilton WD, Heaven B, Thomson GR, Wilson AJ, Exley C. Multidisciplinary
team decision-making in cancer and the absent patient: a qualitative study.
BMJ Journals. 2016;6:e012559.
24. Rao K, Manya K, Azad A, Lawrentschuk N, Bolton D, Davis ID, et al. Uro-
oncology multidisciplinary meetings at an Australian tertiary referral Centre–
impact on clinical decision-making and implications for patient inclusion.
BJU Int. 2014;114(Suppl 1):50–4.
25. Rajan S, Foreman J, Wallis MG, Caldas C, Britton P. Multidisciplinary decisions
in breast cancer: does the patient receive what the team has
recommended? Br J Cancer. 2013;108(12):2442–7.
26. Taylor C, Finnegan-John J, Green JS. “No decision about me without me” in
the context of cancer multidisciplinary team meetings: a qualitative
interview study. BMC Health Serv Res. 2014;14:488.
27. Fallowfield L, Langridge C, Jenkins V. Communication skills training for
breast cancer teams talking about trials. Breast (Edinburgh, Scotland). 2014;
23(2):193–7.
28. El Saghir N, Charara R, Kreidieh F, Eaton V, Litvin K, Farhat R, Khoury K,
Breidy J, Tamim H, Eid T. Global practice and efficiency of multidisciplinary
tumor boards: results of an American Society of Clinical Oncology
international survey. J Global Oncol. 2015;1(2):57–64.
29. Jalil R, Ahmed M, Green JS, Sevdalis N. Factors that can make an
impact on decision-making and decision implementation in cancer
multidisciplinary teams: an interview study of the provider perspective.
Int J Surg. 2013;11(5):389–94.
30. Oxenberg J, Papenfuss W, Esemuede I, Attwood K, Simunovic M, Kuvshinoff
B, et al. Multidisciplinary cancer conferences for gastrointestinal
malignancies result in measureable treatment changes: a prospective study
of 149 consecutive patients. Ann Surg Oncol. 2015;22(5):1533–9.
31. Ryan J, Faragher I. Not all patients need to be discussed in a colorectal
cancer MDT meeting. Color Dis. 2014;16(7):520–6.
32. Harris J, Green JS, Sevdalis N, Taylor C. Using peer observers to assess the
quality of cancer multidisciplinary team meetings: a qualitative proof of
concept study. J Multidiscip Healthc. 2014;7:355–63.
33. Lamb BW, Wong HW, Vincent C, Green JS, Sevdalis N. Teamwork and team
performance in multidisciplinary cancer teams: development and evaluation
of an observational assessment tool. BMJ Qual Saf. 2011;20(10):849–56.
34. Harris J, Taylor C, Sevdalis N, Jalil R, Development GJS. Testing of the cancer
multidisciplinary team meeting observational tool (MDT-MOT). International
journal for quality in health care : journal of the international society for.
Quality in Health Care. 2016;28(3):332–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Rosell et al. BMC Health Services Research  (2018) 18:249 Page 10 of 10
